✦ LIBER ✦

Improving survival in patients with transformed B cell non Hodgkin lymphoma: consolidation with 90Yttrium ibritumomab tiuxetan-BEAM and autologous stem cell transplantation

✍ Scribed by Marielle J. Wondergem; Josee M. Zijlstra; Madelon de Rooij; Otto J. Visser; Peter C. Huijgens; Sonja Zweegman

Book ID: 114714604
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 66 KB
Volume: 157
Category: Article
ISSN: 0007-1048
DOI: 10.1111/j.1365-2141.2011.08991.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Yttrium-90–ibritumomab tiuxetan (Zevalin

Yttrium-90–ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma

✍ Avichai Shimoni; S. Tzila Zwas; Yakov Oksman; Izhar Hardan; Noga Shem-Tov; Ronit 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 186 KB

Long-term responses in patients with rec

Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan

✍ Thomas E. Witzig; Arturo Molina; Leo I. Gordon; Christos Emmanouilides; Russell 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 205 KB

## Abstract ## BACKGROUND. Radioimmunotherapy with radiolabeled monoclonal antibodies to CD20 produces a high response rate in patients with recurring non‐Hodgkin lymphoma (NHL), but the durability of those remissions is not well defined. ## METHODS. Data on patients with recurring NHL treated w

Current status and future perspectives f

Current status and future perspectives for yttrium-90 (90Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma

✍ Gisselbrecht, C; Bethge, W; Duarte, R F; Gianni, A M; Glass, B; Haioun, C; Marti 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 223 KB

Ibritumomab tiuxetan (Zevalin) combined

Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphoma

✍ Shimoni, A; Zwas, S T; Oksman, Y; Hardan, I; Shem-Tov, N; Rand, A; Yerushalmi, R 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 155 KB

High activity 90Y-ibritumomab tiuxetan (

High activity 90Y-ibritumomab tiuxetan (Zevalin®) with peripheral blood progenitor cells support in patients with refractory/resistant B-cell non-Hodgkin lymphomas

✍ Pier F. Ferrucci; Anna Vanazzi; Chiara M. Grana; Marta Cremonesi; Mirco Bartolom 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 242 KB

Biodistribution, radiation dosimetry and

Biodistribution, radiation dosimetry and scouting of90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin’s lymphoma using89Zr-ibritumomab tiuxetan and PET

✍ Saiyada N. F. Rizvi; Otto J. Visser; Maria J. W. D. Vosjan; Arthur van Lingen; O 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 284 KB